Fennec Pharmaceuticals Inc. (TSE:FRX) insider S.P.A. Essetifin purchased 294,115 shares of the business’s stock in a transaction dated Tuesday, December 12th. The stock was bought at an average cost of C$8.50 per share, with a total value of C$2,499,977.50.
Fennec Pharmaceuticals Inc. (FRX) opened at C$11.68 on Friday. Fennec Pharmaceuticals Inc. has a one year low of C$2.30 and a one year high of C$16.23.
Separately, Laidlaw assumed coverage on Fennec Pharmaceuticals in a report on Wednesday, November 29th. They issued a “buy” rating and a C$22.00 price target for the company.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
What are top analysts saying about Fennec Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fennec Pharmaceuticals and related companies.